Balaji Amines Q1 FY27 Results: Net Profit Jumps Sharply as DME Plant Goes Live
By Kaushik Brahmakshatriya
Published On 28 July 2026.
Balaji Amines Q1 FY27 results
Balaji Amines, one of India’s leading manufacturers of aliphatic amines and specialty chemicals, has announced its Balaji Amines Q1 FY27 results for the quarter ended June 30, 2026. The board approved the unaudited standalone and consolidated financial results on July 27, 2026. The company posted robust growth in both revenue and profit, supported by the commissioning of its Dimethyl Ether (DME) plant, marking India’s first commercial-scale facility of its kind. This report highlights the key numbers, business drivers, and outlook for investors and industry watchers alike.
Q1 FY27 Revenue and Profit Performance
The company’s consolidated revenue from operations stood at ₹461 crore for the quarter, reflecting healthy year-on-year growth compared to ₹367 crore reported in Q1 FY26. EBITDA came in at ₹121 crore, indicating a strong margin expansion driven by improved capacity utilization and stable input costs. Consolidated net profit rose sharply to ₹78.12 crore (Rs 7,811.77 lakh), more than double the ₹37.99 crore posted in the corresponding quarter last year. This performance reinforces the Balaji Amines Q1 FY27 results as one of the company’s strongest quarterly showings in recent years.
DME Plant Inauguration: Driving Business Expansion
A major highlight of the quarter was the successful commissioning of the company’s DME (Dimethyl Ether) plant, positioned as India’s first commercial-scale facility of its kind. Management had earlier indicated this project would begin contributing from Q1 FY27 onward, and the timely rollout adds a new revenue stream alongside the core amines and specialty chemicals business. This expansion aligns with the company’s stated target of 10-15% volume growth and a 22-23% EBITDA margin for FY27.
Segment Performance and Future Business Outlook
The Amines & Speciality Chemicals segment continued to be the primary revenue contributor, while the Hotel Division added modest supplementary income. Improved realizations and steady raw material pricing supported margin expansion during the quarter. With capacity additions coming online and export demand from pharmaceutical, agrochemical, and water treatment industries remaining steady, the company appears well-positioned for continued momentum through the rest of FY27.
| Financial Metric | Q1 FY27 | Q1 FY26 | Ll |
| Revenue from Operations | ₹461 crore | ₹367 crore | ~25.6% |
| EBITDA | ₹121 crore | N/A | — |
| Net Profit (PAT) | ₹78.12 crore | ₹37.99 crore | ~105.6% |
FAQ
Q1: What is Balaji Amines’ net profit for Q1 FY27?
A: Consolidated net profit stood at ₹78.12 crore, up sharply from ₹37.99 crore in Q1 FY26.
Q2: What is the DME plant commissioned by Balaji Amines?
A: It is India’s first commercial-scale Dimethyl Ether production facility, now contributing to revenue.
Q3: When were the Q1 FY27 results announced?
A: The board approved the results on July 27, 2026.
Conclusion
The Balaji Amines Q1 FY27 results reflect a strong turnaround, with revenue and profit both showing healthy double-digit growth. The commissioning of the DME plant adds a fresh growth lever, supporting management’s optimistic FY27 outlook. Investors will likely watch upcoming quarters closely to assess sustained momentum across segments and capacity utilization trends.
Disclaimer
This article is for informational purposes only and should not be considered investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.We are not responsible for any loss.
